#None #food allergy #DelveInsight #therapies

Rising Innovations in Food Allergy Management

The landscape of food allergy treatment is rapidly evolving, thanks to a dynamic clinical pipeline that promises a range of innovative therapies. Key players like DBV Technologies, Novartis, and Aravax are making strides with new programs aimed at alleviating food allergies, a growing health concern that affects millions worldwide. The conventional approach has long been strict avoidance of allergens and prompt use of adrenaline in emergencies. However, with the advent of new therapies, the narrative is changing.

Current Standard of Care

Currently, patients are advised to strictly avoid allergens and carry an adrenaline auto-injector (AAI) for use in case of anaphylaxis. While medications such as antihistamines and corticosteroids are frequently used to manage symptoms, they do not address anaphylaxis itself. Adrenaline stays as the first-line treatment, typically administered intramuscularly. However, emerging options like intranasal and sublingual formulations are being developed to improve convenience, reduce anxiety associated with needles, and minimize the burden of carrying injectables.

The Shift to Innovative Therapies

Despite the emphasis on allergen avoidance, new therapeutic strategies aim to modify the body's allergic response. The concept of Oral Immunotherapy (OIT) has gained traction, where gradual exposure to food allergens can lead to desensitization. However, challenges remain, including identifying suitable candidates based on allergy profiles and widening the applications beyond just peanuts to include other allergens.

Current Key Approved Treatments

Among the notable approved treatments are peanut allergen powder (PALFORZIA), omalizumab (XOLAIR), and the epinephrine nasal spray (NEFFY). PALFORZIA is specifically aimed at managing peanut allergies, whereas XOLAIR targets multiple food allergens. The industry is backing the extensive development of novel therapies through a solid clinical pipeline, with various investigational drugs currently under evaluation.

Emerging Therapies to Watch

Several promising treatments are in clinical development, showcasing innovation:

1. DBV Technologies' Viaskin Peanut and Milk Patches
These patches deliver small amounts of allergens through the skin, aiming to promote immune tolerance safely without requiring oral exposure. Viaskin Peanut is currently advancing through Phase III trials, while Viaskin Milk is in Phase I/II.

2. Aquestive Therapeutics' Epinephrine Sublingual Film (ANAPHYLM)
This is a new epinephrine delivery system designed to dissolve in the mouth, making it easy to administer during severe allergic reactions and enhancing portability with its compact form.

3. Novartis' Remibrutinib (LOU064)
An oral Bruton's tyrosine kinase inhibitor, Remibrutinib showcases rapid symptom relief and a favorable safety profile. It is currently in Phase II trials for food allergies, with Phase III anticipated.

4. Aravax's PVX108
A next-generation immunotherapy that targets T cells to retrain the immune system while minimizing risks associated with conventional therapies. It's currently in Phase II clinical trials.

5. GSK's Ozureprubart (RPT904)
This monoclonal antibody is designed for food allergies and chronic spontaneous urticaria, showing promise in early trials.

Market Outlook

According to health market analysts, sustained innovation and enhanced awareness in the food allergy treatment sector are expected to fuel robust growth. By 2025, the market across the seven major markets is projected to reach around USD 2.7 billion, with a compound annual growth rate (CAGR) of 9.4% forecasted until 2036. The increasing awareness of food allergies, first-in-class therapies, and better genetic testing will further expand the market and create commercial opportunities.

Conclusion

The food allergy treatment landscape is at a significant turning point. With many new therapies on the verge of approval, there is hope that individuals with food allergies may experience significantly improved quality of life. As these therapies undergo clinical evaluation, the medical community remains optimistic about the potential they hold in reshaping food allergy management in the years to come.